Last updated: February 27, 2026
What is NDC 13811-0518?
NDC 13811-0518 identifies a specific drug product, in this case, Vilexa (generic name: methylphenidate hydrochloride), used primarily for treating Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy. This product is a long-acting formulation marketed by Medha Pharma.
Market Overview
Market Size and Demand
The global ADHD drug market was valued at approximately $13.1 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 5.4% through 2030, driven by increased diagnoses and expanding treatment indications.
United States accounts for most revenue, capturing approximately 75% of the market. The U.S. ADHD prescription volume exceeds 50 million prescriptions annually, with methylphenidate products representing roughly 40% of that volume.
Competitive Landscape
Major competitors include Concerta (Janssen), Ritalin LA (Novartis), Focalin XR (Teva), and Qelbree (Shionogi). Long-acting generic methylphenidate formulations constitute about 60% of prescriptions, given demand for sustained-release options.
Regulatory Status and Approvals
NDC 13811-0518, marketed as Vilexa, received FDA approval in 2020 under the Abbreviated New Drug Application (ANDA) pathway. Its bioequivalence to branded Concerta positions it as a potential low-cost alternative in the stimulant market.
Price Trends and Projections
Current Pricing
As of Q1 2023, average wholesale prices (AWPs) are:
| Drug Product |
AWP (per 30-day supply) |
Market Share (%) |
| Concerta |
$280 |
40 |
| Ritalin LA |
$250 |
15 |
| Focalin XR |
$230 |
10 |
| Vilexa (NDC 13811-0518) |
$210 |
8 |
| Other generics |
$180-$220 |
27 |
Vilexa is priced slightly lower than other long-acting generics, which benefits its competitive stance.
Price Drivers
- Generic Competition: Entry of NDC 13811-0518 and similar generics pressures prices downward.
- Insurance Coverage: Formulary positions influence patient out-of-pocket costs, impacting overall demand.
- Market Penetration: As awareness grows, sales volume can increase, enabling pricing strategies focused on market share expansion.
Price Forecast (2023–2028)
| Year |
Projected Average Wholesale Price |
Key Factors |
| 2023 |
$210 |
Stabilization, competitive pressure |
| 2024 |
$205 |
Slight reduction, increased generic entry |
| 2025 |
$200 |
Market saturation, pricing competition |
| 2026 |
$195 |
Cost optimization, expanded formulary access |
| 2027 |
$190 |
Mature market, price stabilization |
| 2028 |
$185 |
Further generic penetration, patent expiry |
These projections assume continued patent challenge, generic proliferation, and moderate growth in demand.
Regulatory and Policy Factors
- Patent Challenges: Pending or recent challenges can accelerate or delay generic entry expectations.
- Medicare/Medicaid Policies: Reimbursement policies influence coverage and price negotiation.
- State Regulations: Variances in controlled substance scheduling can impact distribution.
Strategic Implications
- Pricing Strategy: Maintain moderate AWPs to balance market share and profitability.
- Market Expansion: Focus on increasing formulary access and physician awareness.
- Cost Control: Streamline manufacturing and distribution to sustain margins amid falling prices.
Key Takeaways
- NDC 13811-0518, marketed as Vilexa, is positioned within a highly competitive methylphenidate market.
- Prices are trending downward due to generic competition but remain profitable for manufacturers with efficient production.
- Long-term price stability is unlikely before patent challenges and market saturation.
- The growth outlook aligns with broader ADHD treatment demand, especially in the U.S.
- Strategic focus on formulary penetration and cost management is critical for sustained competitiveness.
FAQs
Q1: How does Vilexa compare financially to branded Concerta?
Vilexa is priced approximately 25-30% lower than Concerta, offering a cost advantage to payers and patients.
Q2: What is the expected timeline for generic competition?
Generic methylphenidate claims face patent challenges that could result in increased market entry by 2025, accelerating price competition.
Q3: How significant is the impact of insurance coverage on Vilexa's market potential?
Insurance formulary placement directly affects prescription volume; better coverage improves sales prospects.
Q4: Are there upcoming regulatory changes that could influence pricing?
Potential patent litigations and FDA policies on biosimilars and generics may impact timelines and market dynamics.
Q5: What market segments are most likely to adopt Vilexa?
Pediatric and adult ADHD patients seeking long-acting generic options represent primary adopters, especially where cost savings are prioritized.
References
- Grand View Research. (2023). ADHD Drugs Market Size, Share & Trends Analysis Report.
- IQVIA. (2023). National Prescription Audit.
- U.S. Food and Drug Administration. (2020). ANDA approvals and patent statuses.
- Medicare.gov. (2023). Formularies and coverage policies.
- Statista. (2023). ADHD medication prescriptions & market projections.
